866-997-4948(US-Canada Toll Free)

Remodulin - Analysis and Forecasts from 2002 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 38 Pages



GlobalDatas pharmaceuticals report, Remodulin Analysis and Forecasts from 2002 to 2020 provides Remodulin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Pulmonary Arterial Hypertension market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Remodulin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Remodulin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Remodulin in the seven major markets
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Pulmonary Arterial Hypertension 4
2.2 Epidemiology 4
2.2.1 Prevalence 4
2.2.2 Mortality 5
2.3 Etiology 5
2.3.1 Scleroderma 5
2.3.2 Sickle Cell Disease 5
2.3.3 HIV/AIDS 5
2.3.4 Drug Abuse and Toxins 5
2.4 Economic Impact of PAH 5
2.5 GlobalData Report Guidance 6

3 Pulmonary Arterial Hypertension (PAH): Market Characterization 7
3.1 PAH Market 7
3.2 PAH Market Forecasts and CAGR 8
3.3 PAH Market : Drivers and Restraints 8
3.3.1 Drivers 9
3.3.2 Barriers 10

4 Classification of PAH 11
4.1 Classification Based on Cause and Clinical Presentation 11
4.1.1 Idiopathic PAH 11
4.1.2 Familial PAH 11
4.1.3 Drug Induced PAH 11
4.1.4 PAH Associated with Other Conditions 11
4.1.5 PAH Associated with Significant Venous or Capillary Involvement 11
4.2 Symptomatic Profile of PAH 11

5 Evolution of PAH Treatments 12

6 Medications 13
6.1 Prostanoids 13
6.1.1 Epoprostenol 13
6.1.2 Treprostinil 13
6.1.3 Iloprost 13
6.1.4 Beraprost 13
6.2 Endothelin Receptor Antagonists 13
6.2.1 Bosentan 13
6.2.2 Ambrisentan 14
6.2.3 Sitaxsentan 14
6.3 Phosphodiesterase Type 5 Inhibitors 14
6.3.1 Sildenafil 14
6.3.2 Tadalafil 14
6.4 Surgical Treatments 14
6.5 Investigational Combination Regimens 15
6.6 New Targets for PAH Therapy 15

7 Market Share by Class in PAH 17

8 Remodulin (treprostinil) 18
8.1 Introduction 18
8.2 Mechanism of Action 18
8.3 Clinical Studies 18
8.4 Approval History of Remodulin 20
8.5 Factors Affecting Sales of Remodulin 20
8.5.1 Remodulin Effectiveness in PAH patients 20
8.5.2 Increased Survival Rates 20
8.5.3 Dual Routes of Administration 20
8.5.4 Advantages of Remodulin over Flolan 20
8.5.5 Safety profile 21
8.6 Drug Evaluation 21
8.6.1 Drug Risk Benefit Score 21
8.6.2 Intensity of Competition 22
8.7 Sales Estimates 22
8.7.1 Target Patient Pool of Remodulin 22
8.7.2 Dosing 23
8.7.3 Market Penetration 23
8.7.4 Annual Cost of Therapy 23
8.7.5 Sales Projections of Remodulin 24

9 PAH Market: Appendix 33
9.1 Market Definitions 33
9.2 List of Abberiviations 33
9.3 Research Methodology 34
9.3.1 Coverage 34
9.3.2 Secondary Research 34
9.3.3 Forecasting 34
9.3.4 Number of Patients Approved to take the Drug 35
9.3.5 Net Penetration of Drug 35
9.3.6 Net Annual Dosing 36
9.3.7 Annual Cost of Therapy 36
9.3.8 Primary Research 36
9.3.9 Expert Panels 36
9.4 Drug Sales Estimates Model 36
9.5 Contact Us 37
9.6 Disclaimer 37
9.7 Sources 37

List of Table


Table 1: PAH, Global, Major Marketed Drugs 7
Table 2: PAH, Global, Pipeline (Phase III) 8
Table 3: PAH Drugs Evolution 12
Table 4: 12- Week Study Results of Remodulin in PAH 19
Table 5: Drug Risk Benefit Score of Remodulin 21
Table 6: Percent of Subjects Reporting Subcutaneous Infusion Site Adverse Events 22
Table 7: Remodulin, PAH, Global, Sales Estimates ($m), 20022020 24
Table 8: Remodulin, PAH, The US, Sales Estimates ($m), 20022020 25
Table 9: Remodulin, PAH, The UK, Sales Estimates ($m), 20122020 26
Table 10: Remodulin, PAH, France, Sales Estimates ($m), 20052020 27
Table 11: Remodulin, PAH, Germany, Sales Estimates ($m), 20052020 28
Table 12: Remodulin, PAH, Italy, Sales Estimates ($m), 20052020 29
Table 13: Remodulin, PAH, Spain, Sales Estimates ($m), 20122020 30
Table 14: Remodulin, PAH, Japan, Sales Estimates ($m), 20132020 31

List of Chart


Figure 1: PAH, Global, Market Size Forecasts ($bn), 20102020 8
Figure 2: PAH, Worldwide, Market Share by Class (%), 2010 17
Figure 3: Time to Clinical Deterioration for PAH patients transitioned from Flolan to Remodulin or placebo (8-Week Study) 19
Figure 4: Drug Model Diagram of Remodulin 23
Figure 5: Remodulin, PAH, Global, Sales Estimates ($m), 20022020 24
Figure 6: Remodulin, PAH, The US, Sales Estimates ($m), 20022020 25
Figure 7: Remodulin, PAH, The UK, Sales Estimates ($m), 20122020 26
Figure 8: Remodulin, PAH, France, Sales Estimates ($m), 20052020 27
Figure 9: Remodulin, PAH, Germany, Sales Estimates ($m), 20052020 28
Figure 10: Remodulin, PAH, Italy, Sales Estimates ($m), 20052020 29
Figure 11: Remodulin, PAH, Spain, Sales Estimates ($m), 20122020 30
Figure 12: Remodulin, PAH, Japan, Sales Estimates ($m), 20132020 31
Figure 13: Remodulin, PAH, Global, Sales Distribution by Country (%), 2014 32
Figure 14: Drug Model Diagram 35
Figure 15: Patients Approved for the Drug 36

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *